SCHEMBL22470482

SCHEMBL22470482

CC(=O)NC(C)(C)CN(C(=O)O)C1(c2ccc(F)c(C(F)(F)F)c2)CC1

nearest known ligand 0.60

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 8/20 0.60
AR P10275 1/20 0.38
RORC P51449 1/20 0.33
TAS1R3 Q7RTX0 2/20 0.33
TAS1R1 Q7RTX1 2/20 0.33
TAS1R2 Q8TE23 2/20 0.33
NOTUM Q6P988 1/20 0.33
UBE2M P61081 1/20 0.32
DCUN1D1 Q96GG9 1/20 0.32
PTPN7 P35236 1/20 0.32
DUSP3 P51452 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29356770 0.90 KCNN4 (0.76) KCNN4ARRORCTAS1R3TAS1R1
SCHEMBL22470256 0.89 KCNN4 (0.62) KCNN4ARTAS1R3TAS1R1TAS1R2
SCHEMBL22470161 0.88 KCNN4 (0.59) KCNN4ARRORCTAS1R3TAS1R1
SCHEMBL22470299 0.84 KCNN4 (0.78) KCNN4ARTAS1R3TAS1R1TAS1R2
SCHEMBL22470244 0.81 KCNN4 (0.56) KCNN4ARUBE2MDCUN1D1
SCHEMBL22470402 0.79 KCNN4 (0.60) KCNN4ARNOTUM
SCHEMBL29353607 0.79 KCNN4 (0.72) KCNN4ARRORCTAS1R3TAS1R1
SCHEMBL27075232 0.79 KCNN4 (0.57) KCNN4ARTAS1R3TAS1R1TAS1R2
SCHEMBL29353670 0.79 KCNN4 (0.79) KCNN4ARTAS1R3TAS1R1TAS1R2
SCHEMBL22470474 0.78 KCNN4 (0.70) KCNN4ARTAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-06-02 US claimed
EP-3941903-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2022-01-26 EP claimed
WO-2020193419-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2020-10-01 WO claimed
US-12006289-B2 Potassium channel inhibitors SANIONA A/S (DK) 2024-06-11 US disclosed
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-06-02 US disclosed
EP-3941903-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2022-01-26 EP disclosed
WO-2020193419-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2020-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KCNN4 57/4885AR 4214/4885RORC 2964/4885
US-12006289-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KCNN4 48/4885AR 3894/4885RORC 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.